Here's the facts about the recent past. I think we all felt that IMGN was cheap on a relative basis a year ago, six months ago and 3 months ago. Relative performance is terrible over every period vs SGEN and vs IBB a biotech ETF. This poor relative performance needs to be addressed at the shareholder meeting.
Last 12 months SGEN + almost 70%, IMGN + less than 20%, IBB + almost 50%
Last 6 months SGEN + 25%, IMGN slightly -, IBB up + 7-8%
3 months SGEN + almost 50%, IMGN + about 25%, IBB + 12%